Third synthetic royalty transaction & second pre-approval deal for DRI – – Further increases portfolio exposure to rare diseases – – Long-dated cashflows, extend portfolio duration – – DRI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback